A2 Biotherapeutics' mission is to beat cancer via tumor-specific targeting by addressing targets gained or lost in cancer cells which unequivocally discriminate tumor from normal tissue. The company is focused on addressing the next frontier in cancer cell therapy, solid tumors. A2 Biotherapeutics leverages a powerful platform designed specifically for cell therapies that enables identification of rare binders derived from antibodies or T-cell receptors, precision binder engineering and optimization, and modular signaling construct designs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/05/19 | $57,000,000 | Series A |
Nextech Invest Samsara BioCapital The Column Group Vida Ventures | undisclosed |
